Skip to main content
3200 results

Phoenix Hosted Tutorials

Certara offers Phoenix Hosted which is a secured and validated Certara AWS cloud workspace where to run Phoenix. PK scientists can now access Phoenix from any type of computer (e.g. Window or Mac) and know that they are using a secure and validated Phoenix. Certara’s deployment experts can optimize the Phoenix application configuration for increased … Continued

https://www.certara.com/training/certara-university/learn/phoenix-hosted-tutorials/

Data-Backed Trial Design– Applying AI to Clinical Outcome Analysis

Global spending on clinical trials is expected to reach $68.9 billion per year by 2025 with the average phase 1 asset taking 10.5 years to reach regulatory approval. As the industry faces demands to innovate faster and reduce costs, having access to high-quality data is critical to designing trials that can reach these goals. The … Continued

https://www.certara.com/on-demand-webinar/data-backed-trial-design-applying-ai-to-clinical-outcome-analysis/

Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies PRINCETON, N.J.— March 7, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based … Continued

https://www.certara.com/pressrelease/certara-announces-the-release-of-simcyp-pbpk-simulator-version-22-expanding-ability-to-simulate-untested-scenarios-for-new-patient-and-therapeutic-types/

The UK Regulatory Landscape for Drugs Three Years into Brexit

By: Claire Dyer, Director Global Submissions; Justin Hay, Senior Director; Daniel Smith, Director Regulatory Strategy Brexit reached a significant milestone at the end of January 2023 – three years since the United Kingdom left the European Union. Whilst we’ll be debating its relative merits and pitfalls for decades to come, here in the pharmaceutical industry … Continued

https://www.certara.com/article/the-uk-regulatory-landscape-for-drugs-three-years-into-brexit/

Certara Announces Transition Plan For Chief Financial Officer

PRINCETON, N.J. – March 1, 2023 – Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.  Mr. Schemick will transition into a newly created position as Senior Vice President, Corporate Operations and Integration, and he will be focused on supporting John’s transition, and … Continued

https://www.certara.com/pressrelease/certara-announces-transition-plan-for-chief-financial-officer/

Common Clinical Trial Disclosure Challenges & Potential Solutions

Pharmaceutical companies are being required to be more transparent through the timely disclosure of more clinical trial data on more registry platforms such as Clinicaltrials.gov in the US and CTIS (Clinical Trial Information System, formerly EUDRA-CT) in Europe. You can read more about the changes that come with the rollout of CTIS in this blog. … Continued

https://www.certara.com/blog/common-clinical-trial-disclosure-challenges-potential-solutions/

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

PRINCETON, N.J.— February 1, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued

https://www.certara.com/pressrelease/certara-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-1st-2023/
1 of 320